Literature DB >> 8306532

Antimetastatic action and toxicity on healthy tissues of Na[trans-RuCl4(DMSO)Im] in the mouse.

R Gagliardi1, G Sava, S Pacor, G Mestroni, E Alessio.   

Abstract

The ruthenium-dimethylsulfoxide complex Na(trans-RuCl4(DMSO)Im] was given i.v. to mice bearing MCa mammary carcinoma and its effects on tumor growth and on healthy host tissues were studied by macroscopic examination of primary tumor growth, by survival time, and by histological analysis using light microscopy and SEM. Either by means of vivo-vivo bioassays or by microscopic examination it appeared that the growth of lung tumors was markedly reduced, whereas the growth of the i.m. primary tumor was much less affected. These effects account for the prolongation of survival time and for the cure rate observed. The favourable effect on survival time was also influenced by the lack of significant cytotoxicity for normal tissues such as lung and kidney epithelia, muscle and liver cells, splenocytes and bone marrow. It thus appears that the selective interaction with tumor cells in the lungs cannot simply be attributed to a selectively higher localization of the compound at this site, nor to a modification of the histological structure of primary tumor. These results highlight the pharmacologic properties of this compound for the control of solid tumor metastases, an effect that was shown to be similarly exerted on advanced tumor metastases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8306532     DOI: 10.1007/BF01753975

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  11 in total

1.  Tumor heterogeneity: biological implications and therapeutic consequences.

Authors:  G H Heppner; B E Miller
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

2.  97Ru-transferrin uptake in tumor and abscess.

Authors:  P Som; Z H Oster; K Matsui; G Guglielmi; B R Persson; M L Pellettieri; S C Srivastava; P Richards; H L Atkins; A B Brill
Journal:  Eur J Nucl Med       Date:  1983

3.  Na[trans-RuCl4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties.

Authors:  G Sava; S Pacor; G Mestroni; E Alessio
Journal:  Clin Exp Metastasis       Date:  1992-07       Impact factor: 5.150

Review 4.  Metal complexes of ruthenium: antineoplastic properties and perspectives.

Authors:  G Sava; S Pacor; F Bregant; V Ceschia; G Mestroni
Journal:  Anticancer Drugs       Date:  1990-12       Impact factor: 2.248

5.  Effects of the Ru(III) complexes [mer-RuCl3(DMSO)2Im]degrees and Na[trans-RuCl4(DMSO)Im] on solid mouse tumors.

Authors:  G Sava; S Pacor; G Mestroni; E Alessio
Journal:  Anticancer Drugs       Date:  1992-02       Impact factor: 2.248

Review 6.  Shaping future strategies for the pharmacological control of tumor cell metastases.

Authors:  R G Greig; D L Trainer
Journal:  Cancer Metastasis Rev       Date:  1986       Impact factor: 9.264

7.  The selective nature of metastasis.

Authors:  J E Talmadge
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

8.  Morphological analysis of metastatic potential and antimetastatic drug effects in mice bearing two lines of Lewis lung carcinoma.

Authors:  V Grill; F Mallardi; S Zorzet; L Perissin; T Giraldi
Journal:  Clin Exp Metastasis       Date:  1987-09       Impact factor: 5.150

9.  Tissue distributions of 97Ru and 103Ru in subcutaneous tumor of rodents.

Authors:  M Tanabe; G Yamamoto
Journal:  Acta Med Okayama       Date:  1975-12       Impact factor: 0.892

10.  Fractional incorporation of [3H]thymidine and DNA specific activity as assays of inhibition of tumour growth.

Authors:  P J Houghton; D M Taylor
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  5 in total

1.  Comparison of the effects of the antimetastatic compound ImH[trans-RuCl4(DMSO)Im] (NAMI-A) on the arthritic rat and on MCa mammary carcinoma in mice.

Authors:  G Sava; R Gagliardi; M Cocchietto; K Clerici; I Capozzi; M Marrella; E Alessio; G Mestroni; R Milanino
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

Review 2.  Ruthenium-based chemotherapeutics: are they ready for prime time?

Authors:  Emmanuel S Antonarakis; Ashkan Emadi
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-06       Impact factor: 3.333

3.  Synthesis, structure and biological evaluation of ruthenium(III) complexes of triazolopyrimidines with anticancer properties.

Authors:  Marzena Fandzloch; Liliana Dobrzańska; Tomasz Jędrzejewski; Julia Jezierska; Joanna Wiśniewska; Iwona Łakomska
Journal:  J Biol Inorg Chem       Date:  2019-11-18       Impact factor: 3.358

4.  Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex.

Authors:  G Sava; I Capozzi; K Clerici; G Gagliardi; E Alessio; G Mestroni
Journal:  Clin Exp Metastasis       Date:  1998-05       Impact factor: 5.150

5.  Radiosensitisation of human colorectal cancer cells by ruthenium(II) arene anticancer complexes.

Authors:  R Carter; A Westhorpe; M J Romero; A Habtemariam; C R Gallevo; Y Bark; N Menezes; P J Sadler; R A Sharma
Journal:  Sci Rep       Date:  2016-02-12       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.